Waiting for perfect data before deploying AI is a trap — and why 60-70% accuracy is often good enough to start.

Fox Rothschild's Mark Wagner on why the FDA counts 70 drugs in shortage while ASHP counts 188 — and what's driving the gap.

Pharma's chain of custody model is migrating into food and consumer goods — and becoming a cross-industry differentiator.

Pharma logistics are overqualified by design — and how agentic AI can now optimize across thousands of lanes in days, not months.

Pharma AI adoption fails not because of the technology — but because organizations deploy tools before they're ready to use them.

CORXEL’s Dr. Bo Liang on why GLP-1 therapies are a broader chronic disease platform — not just obesity drugs — with benefits across cardiovascular, renal, and metabolic disease.

Why GLP-1s achieving bariatric surgery-level efficacy is the field's most surprising advancement of the past decade.

Thomas Appio has been named interim CEO of Bausch + Lomb, a move coinciding with an expected upward revision to the company’s full-year guidance.